Skip to main content
. Author manuscript; available in PMC: 2014 Apr 25.
Published in final edited form as: J Med Chem. 2013 Apr 3;56(8):3429–3433. doi: 10.1021/jm4001874

Table 1.

Affinity, liphopilicity, and molecular weight of pyraxolopyrimidines

graphic file with name nihms464016u1.jpg
Compd R1 R2 R3 R4 MW LogP7.5 Ki (nM)δ
5aα -Me -H -Me -OMe 366.21 2.40 12.23
5b -Et -H -Et -OMe 394.51 2.84 0.18
5cβ -iPr -H -iPr -OMe 422.56 2.98 >500
5d -Me -Me -Me -OMe 380.48 2.45 93.75
5e -Me -Et -Me -OMe 394.51 2.78 157.14
5f -Me -CH2C(O)CH3 -Me -OMe 408.49 2.57 200.89
5g -Me -Cl -Me -OMe 400.9 2.99 55.36
6aγ -Me -H -Me -OCH2CH2F 398.47 2.12 9.73
6b -Et -H -Et -OCH2CH2F 426.53 2.50 0.27ε
6c -iPr -H -iPr -OCH2CH2F 454.58 2.73 >500
6d -Me -Me -Me -OCH2CH2F 412.5 2.47 83.04
6e -Me -Et -Me -OCH2CH2F 426.53 2.53 276.79
6f -Me -CH2C(O)CH3 -Me -OCH2CH2F 440.51 2.07 251.79
6g -Me -Cl -Me -OCH2CH2F 432.92 2.55 67.86
α

DPA-713, see references.710

β

See reference.11

γ

DPA-714, see references.79, 12

δ

Competitive binding against 3H-PK 11195 in C6 glioma cell lysate.

ε

Ki versus 3H-flunitrazepam > 10,000 nM.

HHS Vulnerability Disclosure